Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Capital Expenditures (2017 - 2025)

Crinetics Pharmaceuticals has reported Capital Expenditures over the past 9 years, most recently at $5.7 million for Q4 2025.

  • For Q4 2025, Capital Expenditures rose 4734.75% year-over-year to $5.7 million; the TTM value through Dec 2025 reached $5.8 million, up 3101.11%, while the annual FY2025 figure was $5.8 million, 3101.11% up from the prior year.
  • Capital Expenditures for Q4 2025 was $5.7 million at Crinetics Pharmaceuticals, up from -$30000.0 in the prior quarter.
  • Over five years, Capital Expenditures peaked at $5.7 million in Q4 2025 and troughed at -$2.2 million in Q3 2024.
  • A 5-year average of $669578.9 and a median of $82000.0 in 2022 define the central range for Capital Expenditures.
  • Biggest five-year swings in Capital Expenditures: tumbled 275.0% in 2021 and later skyrocketed 16981.82% in 2023.
  • Year by year, Capital Expenditures stood at $18000.0 in 2021, then surged by 8766.67% to $1.6 million in 2022, then plummeted by 41.42% to $935000.0 in 2023, then crashed by 87.38% to $118000.0 in 2024, then skyrocketed by 4734.75% to $5.7 million in 2025.
  • Business Quant data shows Capital Expenditures for CRNX at $5.7 million in Q4 2025, -$30000.0 in Q3 2025, and -$177000.0 in Q2 2025.